ClinicalTrials.gg
CompletedNCT03405870LIPIDS-PUpdated Aug 11, 2025Results posted

LIPIDS-P Trial Phase I/II Trial

A Phase 1/2 interventional study of Smoflipid in Sepsis, Severe and Septic Shock, sponsored by University of Florida. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's listed conditions name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Florida · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 164 studies in Shock, Septic with a site in United States — 19 open to participants now, 26 under way, 1 of them phase 3. Shock, Septic · United States.

Enrollment
52nd of 116
59 · median 50
Started
2018
with 12 others
Phase 1/2
7 of 164
none open now
Registered
96th of 164
by date

Among the 164 studies in Shock, Septic with a site in United States, this one is the 52nd largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 7 in phase 1/2, and was the 96th registered.

Shock, Septic

1,080 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

19 of the 164 studies in Shock, Septic with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 102 (74%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Shock, Septic with a site in United States, or all of them as a file.
02

Study summary

Briefly, this pilot clinical trial will evaluate preliminary safety and efficacy of the study drug (Smoflipid) at elevating cholesterol levels (primary outcome) in patients with sepsis and moderate organ dysfunction and will also evaluate measures of organ dysfunction, mortality, and biological activity (secondary outcomes).

Read the detailed description

Sepsis is a life-threatening disease for which there are no effective treatments. It results from metabolic and immunologic derangements that lead to organ dysfunction, shock and sometimes death. Both "good" (high density lipoprotein, HDL) and "bad" (low density lipoprotein, LDL) cholesterol should be protective against sepsis by helping to clear bacterial toxins from the blood stream and by providing a fuel for endogenous corticosteroids, part of the body's protective stress-response in shock. However, for partially unknown reasons, cholesterol levels drop to critically low levels in early sepsis, leaving the body unable to protect itself against sepsis via these mechanisms. Currently, lipid emulsions are available that are FDA approved for intravenous nutrition in critically ill patients (including sepsis) and may be capable of elevating serum cholesterol levels. This Phase II randomized pilot clinical trial, proposes to assess the following in a cohort of patients with early sepsis (first 24 hours): 1) safety and tolerability of the proposed lipid injectable emulsion (Smoflipid) and any adverse effects, 2) the drugs ability to optimally elevate cholesterol at 48 hours, and 3) preliminary measures of biological activity and clinical outcomes.

03

Conditions studied

  • Sepsis, Severe
  • Septic Shock

Browse trials for

Keywords

  • cholesterol
  • lipids
  • total parenteral nutrition
04

In context

Shock, Septic Reclassified

1,080 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.

This study's enrollment of 59 is below the median of 80 across 636 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

University of Florida is the lead sponsor of 1,289 studies on the registry; 201 are open to participants now.

Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age > 18,
  2. primary diagnosis of sepsis and within 24 hours of sepsis recognition and treated with institutional sepsis algorithm,
  3. SOFA score ≥ 4,
  4. screening total cholesterol ≤ 100 mg/dL or HDL-C + LDL-C ≤ 70 mg/dL

Exclusion criteria

Exclusion Criteria:

  1. total > 2 mg/dL,
  2. serum albumin \< 1.5 mg/dL,
  3. to fish, egg, soybean, or peanut protein, or to any of the active ingredients or ,
  4. severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides > 400 mg/dL,
  5. alternative/confounding diagnosis causing shock or critical illness (e.g., myocardial infarction or pulmonary embolus, massive hemorrhage, trauma),
  6. significant traumatic brain injury (evidence of neurologic injury on CT scan and a GCS \<8),
  7. shock (likely death within 12 hours),
  8. established Do Not Resuscitate status or advanced directives restricting aggressive care or treating physician deems aggressive care unsuitable,
  9. anticipated requirement for surgery that would interfere with drug infusion,
  10. severe primary blood coagulation disorder,
  11. acute pancreatitis accompanied by hyperlipidemia,
  12. acute thromboembolic disease,
  13. uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable dead bowel),
  14. severe state (e.g. subject has neutropenia receiving cytotoxic chemotherapy with \< 500/ul or expected to decline to \< 500/uL within the next 3 days),
  15. pregnancy or lactation
  16. already receiving intravenous lipid formulations (e.g., TPN, propofol) will be excluded from the study as lipid infusion will interfere with interpretation of the study results.
  17. Class B/C liver disease patients or liver transplant recipient
  18. Patients on, or anticipated to be placed on, ECMO within 48 hours of enrollment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Phase II - 1.2 g/kg Smoflipid

    Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.

    Drug: Smoflipid

  • Experimental
    Phase II - 1.4 g/kg Smoflipid

    Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.

    Drug: Smoflipid

  • Experimental
    Phase II - 1.6 g/kg Smoflipid

    Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.

    Drug: Smoflipid

  • No intervention
    Phase II - Control

    No drug, patients will be followed as active controls

  • Experimental
    Phase I - 1.0 g/kg Smoflipid

    Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.

    Drug: Smoflipid

  • Experimental
    Phase I - 1.2 g/kg Smoflipid

    Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.

    Drug: Smoflipid

  • Experimental
    Phase I - 1.4 g/kg Smoflipid

    Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.

    Drug: Smoflipid

  • Experimental
    Phase I - 1.6 g/kg Smoflipid

    Infusion of drug (Smoflipid) will occur over a 10-16.5 hour period given once per day for the first two days of study enrollment.

    Drug: Smoflipid

Interventions

  • Administration of lipid injectable emulsion

    Also known as: Total parenteral nutrition

07

What researchers measure

Primary outcomes

  1. Phase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment)

    Change in total cholesterol (48 hour - enrollment value) of 0 to +5 mg/dL

    Time frame: 48 hours

  2. Phase I - Primary Outcome - Maximum Tolerated Dose/Participants Experiencing Dose Related Toxicity

    Using sequential dose escalation, participants received 2 doses of 1.0 to 1.6 g/kg of lipid emulsion (Smoflipid 20% lipid emulsion) within 48 hours of enrollment to test the maximum tolerated dose of study drug. The maximum tolerated dose was defined by patients exhibiting specific dose-related toxicities from administration of escalating doses of the study drug. Of 9 patients, adverse events were only considered dose-limiting toxicities if they met the predefined study protocol criteria. None of these were classified as dose limiting or serious.

    Time frame: First 48 hours

Secondary outcomes

  1. Phase II - Secondary Outcome - Organ Dysfunction

    Sequential Organ Failure Assessment (SOFA) Score, this is a numerical score ranging from 0 to 24. A Higher SOFA score represents worsening organ dysfunction is correlated with higher rate of mortality. We measured the change over 48 hours.

    Time frame: 48 hours

08

Results

Posted Aug 11, 2025
Limitations and caveats
For the Phase I trial, the main limitation was the small sample of patients; however, this is not uncommon among phase I trials. The Phase II was also a small clinical trial of 47 patients, planned for 24 patients in each arm. Strict enrollment criteria limited enrollment in this study and the exclusion of patients with elevated bilirubin given the drug's hepatic metabolism and risk of complications limited the number of patients who could enroll.

Participant flow

The study has a Phase II design. After evaluating for DLT, 49 enrolled (2 withdrawals) with 47 patients completing the Phase II study to either Smoflipid (intervention) or control. Only Phase II data are reported here.

Participant flow — Overall Study
MilestonePhase II - 1.2 g/kg SmoflipidPhase II - 1.4 g/kg SmoflipidPhase II - 1.6 g/kg SmoflipidPhase II - ControlPhase I - 1.0 g/kg SmoflipidPhase I - 1.2 g/kg SmoflipidPhase I - 1.4 g/kg SmoflipidPhase I - 1.6 g/kg Smoflipid
Started11410242233
Completed1049242223
Not completed10100010
Withdrew: Withdrawal10100010

Outcome measures

PrimaryPhase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment)

Change in total cholesterol (48 hour - enrollment value) of 0 to +5 mg/dL

Time frame:
48 hours
Reported as:
Mean · mg/dL
Phase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment)
mg/dLPhase II - 1.2 g/kg SmoflipidPhase II - 1.4 g/kg SmoflipidPhase II - 1.6 g/kg SmoflipidPhase II - ControlPhase I - 1.0 g/kg SmoflipidPhase I - 1.2 g/kg SmoflipidPhase I - 1.4 g/kg SmoflipidPhase I - 1.6 g/kg Smoflipid
Phase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment)9 ± 17-10 ± 294 ± 212 ± 18-12 ± 2316 ± 1-9 ± 10-18 ± 9
PrimaryPhase I - Primary Outcome - Maximum Tolerated Dose/Participants Experiencing Dose Related Toxicity

Using sequential dose escalation, participants received 2 doses of 1.0 to 1.6 g/kg of lipid emulsion (Smoflipid 20% lipid emulsion) within 48 hours of enrollment to test the maximum tolerated dose of study drug. The maximum tolerated dose was defined by patients exhibiting specific dose-related toxicities from administration of escalating doses of the study drug. Of 9 patients, adverse events were only considered dose-limiting toxicities if they met the predefined study protocol criteria. None of these were classified as dose limiting or serious.

Time frame:
First 48 hours
Reported as:
Count of participants · Participants
Phase I - Primary Outcome - Maximum Tolerated Dose/Participants Experiencing Dose Related Toxicity
ParticipantsPhase II - 1.2 g/kg SmoflipidPhase II - 1.4 g/kg SmoflipidPhase II - 1.6 g/kg SmoflipidPhase II - ControlPhase I - 1.0 g/kg SmoflipidPhase I - 1.2 g/kg SmoflipidPhase I - 1.4 g/kg SmoflipidPhase I - 1.6 g/kg Smoflipid
Phase I - Primary Outcome - Maximum Tolerated Dose/Participants Experiencing Dose Related Toxicity00000000
Statistical analysis
  • Phase I - 1.0 g/kg Smoflipid vs Phase I - 1.2 g/kg Smoflipid vs Phase I - 1.4 g/kg Smoflipid vs Phase I - 1.6 g/kg Smoflipid · Value of maximum tolerated dose (g/kg): 1.6
SecondaryPhase II - Secondary Outcome - Organ Dysfunction

Sequential Organ Failure Assessment (SOFA) Score, this is a numerical score ranging from 0 to 24. A Higher SOFA score represents worsening organ dysfunction is correlated with higher rate of mortality. We measured the change over 48 hours.

Time frame:
48 hours
Reported as:
Median · score on a scale
Phase II - Secondary Outcome - Organ Dysfunction
score on a scalePhase II - 1.2 g/kg SmoflipidPhase II - 1.4 g/kg SmoflipidPhase II - 1.6 g/kg SmoflipidPhase II - ControlPhase I - 1.0 g/kg SmoflipidPhase I - 1.2 g/kg SmoflipidPhase I - 1.4 g/kg SmoflipidPhase I - 1.6 g/kg Smoflipid
Phase II - Secondary Outcome - Organ Dysfunction1 (-2 to 1)0 (-5 to 0)-2 (-3 to -2)-2 (-4 to -1)4 (3 to 4)-5 (-6 to -4)-2 (-3 to 0)0 (-2 to 2)

Adverse events

Collected over Adverse event data were collected from enrollment through 28 days after enrollment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase II - 1.2 g/kg Smoflipid1/10 (10%)2/10 (20%)6/10 (60%)
Phase II - 1.4 g/kg Smoflipid3/4 (75%)3/4 (75%)3/4 (75%)
Phase II - 1.6 g/kg Smoflipid0/9 (0%)1/9 (11.1%)7/9 (77.8%)
Phase II - Control7/24 (29.2%)8/24 (33.3%)8/24 (33.3%)
Phase I - 1.0 g/kg Smoflipid1/2 (50%)2/2 (100%)2/2 (100%)
Phase I - 1.2 g/kg Smoflipid0/2 (0%)0/2 (0%)1/2 (50%)
Phase I - 1.4 g/kg Smoflipid0/2 (0%)0/2 (0%)2/2 (100%)
Phase I - 1.6 g/kg Smoflipid2/3 (66.7%)2/3 (66.7%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventPhase II - 1.2 g/kg SmoflipidPhase II - 1.4 g/kg SmoflipidPhase II - 1.6 g/kg SmoflipidPhase II - ControlPhase I - 1.0 g/kg SmoflipidPhase I - 1.2 g/kg SmoflipidPhase I - 1.4 g/kg SmoflipidPhase I - 1.6 g/kg Smoflipid
IntubationRespiratory, thoracic and mediastinal disorders0/100/40/93/242/20/20/21/3
DeathGeneral disorders1/103/40/97/241/20/20/22/3
Hospital ReadmissionGeneral disorders1/100/41/90/240/20/20/20/3
Vasopressor SupportGeneral disorders0/100/40/91/240/20/20/20/3
Cardiac ArrestCardiac disorders0/100/40/91/240/20/20/20/3
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPhase II - 1.2 g/kg SmoflipidPhase II - 1.4 g/kg SmoflipidPhase II - 1.6 g/kg SmoflipidPhase II - ControlPhase I - 1.0 g/kg SmoflipidPhase I - 1.2 g/kg SmoflipidPhase I - 1.4 g/kg SmoflipidPhase I - 1.6 g/kg Smoflipid
HyperglycemiaGeneral disorders1/100/40/90/241/21/20/21/3
Elevated triglyceridesGeneral disorders2/100/42/93/241/21/20/21/3
Elevated Total BiliGeneral disorders0/101/40/91/241/20/20/20/3
Line infiltrationGeneral disorders0/100/42/90/240/20/21/21/3
Elevated ALTGeneral disorders1/100/41/91/240/20/21/20/3
Elevated ASTHepatobiliary disorders1/100/40/91/241/20/21/20/3
Elevated INRGeneral disorders0/100/41/90/240/20/20/21/3
ThrombocytopeniaGeneral disorders2/101/42/96/240/20/20/20/3
Decreased phosphorusGeneral disorders0/101/40/90/240/20/20/20/3
Elevated creatinineGeneral disorders2/101/41/90/240/20/20/20/3

Baseline characteristics

10 patients were enrolled in the Phase I trial. One patient was withdrawn leaving nine patients for analysis. 49 patients were enrolled in the Phase II trial. Two patients were withdrawn leaving 47 patients who completed the study and were included in the analysis.

Age, Customized
Age, Customized(years)Phase II - 1.2 g/kg SmoflipidPhase II - 1.4 g/kg SmoflipidPhase II - 1.6 g/kg SmoflipidPhase II - ControlPhase I - 1.0 g/kg SmoflipidPhase I - 1.2 g/kg SmoflipidPhase I - 1.4 g/kg SmoflipidPhase I - 1.6 g/kg SmoflipidTotal
Age, y71 (59 to 76)63 (61 to 67)67 (48 to 77)68 (60 to 73)66 (65 to 67)53 (42 to 64)53 (44 to 63)59 (58 to 62)65 (57 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Phase II - 1.2 g/kg SmoflipidPhase II - 1.4 g/kg SmoflipidPhase II - 1.6 g/kg SmoflipidPhase II - ControlPhase I - 1.0 g/kg SmoflipidPhase I - 1.2 g/kg SmoflipidPhase I - 1.4 g/kg SmoflipidPhase I - 1.6 g/kg SmoflipidTotal
Female80210101224
Male24714121132
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase II - 1.2 g/kg SmoflipidPhase II - 1.4 g/kg SmoflipidPhase II - 1.6 g/kg SmoflipidPhase II - ControlPhase I - 1.0 g/kg SmoflipidPhase I - 1.2 g/kg SmoflipidPhase I - 1.4 g/kg SmoflipidPhase I - 1.6 g/kg SmoflipidTotal
American Indian or Alaska Native000000000
Asian000000000
Native Hawaiian or Other Pacific Islander000000000
Black or African American52511110126
White51412112228
More than one race000000000
Unknown or Not Reported010100002
Region of Enrollment
Region of Enrollment(participants)Phase II - 1.2 g/kg SmoflipidPhase II - 1.4 g/kg SmoflipidPhase II - 1.6 g/kg SmoflipidPhase II - ControlPhase I - 1.0 g/kg SmoflipidPhase I - 1.2 g/kg SmoflipidPhase I - 1.4 g/kg SmoflipidPhase I - 1.6 g/kg SmoflipidTotal
United States104924222356
09

Study locations

3 sites
  • Department of Emergency Medicine, UF Health
    Gainesville, Florida 32610, United States
  • UF Health Emergency Medicine
    Gainesville, Florida 32610, United States
  • UF Health Jacksonville North campus
    Jacksonville, Florida 32218, United States
10

References and documents

Publications

  • Augustin B, Wu D, Black LP, Bertrand A, Sulaiman D, Hopson C, Jacob V, Shavit JA, Hofmaenner DA, Labilloy G, Smith L, Cagmat E, Graim K, Datta S, Reddy ST, Guirgis FW. Multiomic molecular patterns of lipid dysregulation in a subphenotype of sepsis with higher shock incidence and mortality. Crit Care. 2024 Dec 24;28(1):431. doi: 10.1186/s13054-024-05216-3. PubMed 39716214 ↗
  • Guirgis FW, Black LP, Henson M, Bertrand A, DeVos E, Ferreira J, Gao H, Wu SS, Leeuwenburgh C, Moldawer L, Moore F, Reddy ST. The Lipid Intensive Drug Therapy for Sepsis Phase II Pilot Clinical Trial. Crit Care Med. 2024 Aug 1;52(8):1183-1193. doi: 10.1097/CCM.0000000000006268. Epub 2024 Mar 15. PubMed 38488429 ↗
  • Guirgis FW, Black LP, DeVos E, Henson M, Ferreira J, Miller T, Rosenthal M, Leeuwenburgh C, Kalynych C, Moldawer L, Jones L, Crandall M, Reddy ST, Gao H, Wu S, Moore F. Lipid intensive drug therapy for sepsis pilot: A Bayesian phase I clinical trial. J Am Coll Emerg Physicians Open. 2020 Nov 18;1(6):1332-1340. doi: 10.1002/emp2.12237. eCollection 2020 Dec. PubMed 33392541 ↗
  • Guirgis FW, Black LP, Rosenthal MD, Henson M, Ferreira J, Leeuwenburgh C, Kalynych C, Moldawer LL, Miller T, Jones L, Crandall M, Reddy ST, Wu SS, Moore FA. LIPid Intensive Drug therapy for Sepsis Pilot (LIPIDS-P): Phase I/II clinical trial protocol of lipid emulsion therapy for stabilising cholesterol levels in sepsis and septic shock. BMJ Open. 2019 Sep 18;9(9):e029348. doi: 10.1136/bmjopen-2019-029348. PubMed 31537565 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Apr 2023, 56 months.

Results were first posted in Aug 2025, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 23, 2018
StartActual
Aug 17, 2018
Primary completionActual
Apr 26, 2023
CompletionActual
Apr 26, 2023
Results first posted
Aug 11, 2025
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03405870
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Aug 17, 2018
Primary completion
Apr 26, 2023
Completion
Apr 26, 2023
Results posted
Aug 11, 2025
Last update
Aug 11, 2025

Study contacts

Faheem W Guirgis, MD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SMOFlipid

Start the discussion